Total Payments
$273,203
2024 Payments
$13,710
Companies
29
Transactions
235
Medicare Patients
1,580
Medicare Billing
$85,474
Payment Breakdown by Category
Consulting$146,803 (53.7%)
Other$54,396 (19.9%)
Travel$49,469 (18.1%)
Research$14,715 (5.4%)
Food & Beverage$5,103 (1.9%)
Education$2,718 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $146,803 | 65 | 53.7% |
| Travel and Lodging | $49,469 | 64 | 18.1% |
| Honoraria | $36,645 | 11 | 13.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,751 | 4 | 6.5% |
| Unspecified | $14,715 | 19 | 5.4% |
| Food and Beverage | $5,103 | 64 | 1.9% |
| Education | $2,718 | 8 | 1.0% |
Payments by Type
General
$258,489
216 transactions
Research
$14,715
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $105,271 | 82 | $0 (2024) |
| SWEDISH ORPHAN BIOVITRUM AB | $27,751 | 12 | $0 (2024) |
| Horizon Therapeutics plc | $27,153 | 14 | $0 (2023) |
| Radius Health, Inc. | $14,913 | 33 | $0 (2024) |
| Daiichi Sankyo Company LTD | $13,312 | 4 | $0 (2019) |
| AbbVie, Inc. | $11,230 | 19 | $0 (2019) |
| GENZYME CORPORATION | $9,868 | 10 | $0 (2020) |
| Horizon Pharma plc | $7,390 | 8 | $0 (2018) |
| Gilead Sciences, Inc. | $6,660 | 5 | $0 (2020) |
| CSL Behring | $6,200 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,710 | 16 | SWEDISH ORPHAN BIOVITRUM AB ($4,824) |
| 2023 | $13,800 | 17 | Horizon Therapeutics plc ($10,101) |
| 2022 | $2,295 | 7 | Radius Health, Inc. ($2,295) |
| 2021 | $3,374 | 1 | Amgen Inc. ($3,374) |
| 2020 | $30,502 | 13 | Horizon Therapeutics plc ($16,531) |
| 2019 | $67,874 | 56 | Amgen Inc. ($26,435) |
| 2018 | $70,300 | 68 | Amgen Inc. ($41,254) |
| 2017 | $71,349 | 57 | Amgen Inc. ($30,273) |
All Payment Transactions
235 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Consulting Fee | Cash or cash equivalent | $2,664.00 | General |
| 12/01/2024 | SWEDISH ORPHAN BIOVITRUM AB | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,160.00 | General |
| 11/15/2024 | Amgen Inc. | EVENITY (Biological), Prolia, XGEVA | Food and Beverage | In-kind items and services | $127.94 | General |
| Category: Bone Health | ||||||
| 11/13/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/10/2024 | Kyowa Kirin, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 09/27/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $61.76 | General |
| Category: Endocrinology | ||||||
| 09/18/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 08/21/2024 | SOBI, INC | — | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
| 07/19/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $862.50 | General |
| 07/12/2024 | Kyowa Kirin Co., Ltd | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 02/29/2024 | Radius Health, Inc. | Tymlos (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $125.56 | General |
| Category: Endocrinology | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $1,107.20 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $281.37 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $275.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $109.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/23/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $16.23 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/08/2023 | Radius Health, Inc. | — | Education | In-kind items and services | $400.00 | General |
| 12/04/2023 | GRT US Holding, Inc. | — | Consulting Fee | Cash or cash equivalent | $757.50 | General |
| 10/15/2023 | UCB SA | — | Food and Beverage | In-kind items and services | $108.39 | General |
| 08/31/2023 | Radius Health, Inc. | Tymlos (Drug) | Education | In-kind items and services | $127.22 | General |
| Category: Endocrinology | ||||||
| 06/26/2023 | Radius Health, Inc. | Tymlos (Drug) | Education | In-kind items and services | $236.67 | General |
| Category: Endocrinology | ||||||
| 04/26/2023 | Radius Health, Inc. | Tymlos (Drug) | Education | In-kind items and services | $817.11 | General |
| Category: Endocrinology | ||||||
| 03/16/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $118.15 | General |
| 03/11/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Honoraria | Cash or cash equivalent | $8,450.00 | General |
| Category: KRYSTEXXA | ||||||
| 03/11/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $1,238.79 | General |
| Category: KRYSTEXXA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GIOP Study | Amgen Inc. | $4,550 | 1 |
| Ph2 RA Study | Amgen Inc. | $3,466 | 2 |
| Ph3 PMO Fracture Study ALN SupVert | Amgen Inc. | $1,750 | 1 |
| Responder Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study | Radius Health, Inc. | $1,081 | 2 |
| Data-driven patient clustering and differential clinical outcomes in the BRASS rheumatoid arthritis registry | SANOFI-AVENTIS U.S. LLC | $959.04 | 2 |
| The Safety and Efficacy of Abaloparatide-SC in Men with Osteoporosis: A Randomized Clinical Trial | Radius Health, Inc. | $925.32 | 3 |
| Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of The BRASS Registry | SANOFI-AVENTIS U.S. LLC | $748.00 | 2 |
| Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling through Principal Component and Cluster Analysis of The Brass Registry | SANOFI-AVENTIS U.S. LLC | $612.00 | 2 |
| Efficacy and Safety of Abaloparatide in Men with Osteoporosis | Radius Health, Inc. | $236.25 | 1 |
| Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women?s Rheumatoid Arthritis Sequential Study (BRASS) Registry | SANOFI-AVENTIS U.S. LLC | $226.44 | 1 |
| Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Womens Rheumatoid Arthritis Sequential Study (BRASS) Registry | SANOFI-AVENTIS U.S. LLC | $146.52 | 1 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Pharmaceuticals U.S.A., Inc. | $13.89 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 362 | 430 | $82,980 | $20,808 |
| 2022 | 5 | 394 | 467 | $81,186 | $21,682 |
| 2021 | 6 | 440 | 509 | $91,833 | $25,394 |
| 2020 | 5 | 384 | 447 | $78,934 | $17,591 |
Total Patients
1,580
Total Services
1,853
Medicare Billing
$85,474
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 155 | 214 | $52,644 | $13,840 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 21 | 30 | $10,470 | $3,155 | 30.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $9,671 | $2,223 | 23.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Facility | 2023 | 121 | 121 | $6,534 | $1,081 | 16.5% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 35 | 35 | $1,890 | $307.38 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 11 | $1,771 | $201.51 | 11.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 139 | 206 | $50,676 | $14,427 | 28.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $9,671 | $2,334 | 24.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 18 | $6,282 | $1,819 | 29.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Facility | 2022 | 180 | 180 | $9,720 | $1,703 | 17.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 22 | 23 | $3,703 | $1,201 | 32.4% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 21 | 21 | $1,134 | $197.70 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 139 | 189 | $46,494 | $13,232 | 28.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 30 | 46 | $16,054 | $5,047 | 31.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $10,689 | $2,856 | 26.7% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Facility | 2021 | 203 | 203 | $10,962 | $1,951 | 17.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 30 | 32 | $4,736 | $1,348 | 28.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 18 | $2,898 | $959.22 | 33.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 143 | 193 | $47,478 | $9,665 | 20.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 26 | 26 | $13,234 | $2,956 | 22.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 51 | 60 | $5,726 | $2,378 | 41.5% |
| 77080 | Bone density measurement using dedicated x-ray machine | Facility | 2020 | 136 | 136 | $7,344 | $1,338 | 18.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 28 | 32 | $5,152 | $1,254 | 24.3% |
About Kenneth Saag
Kenneth Saag is a Rheumatology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023033917.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kenneth Saag has received a total of $273,203 in payments from pharmaceutical and medical device companies, with $13,710 received in 2024. These payments were reported across 235 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($146,803).
As a Medicare-enrolled provider, Saag has provided services to 1,580 Medicare beneficiaries, totaling 1,853 services with total Medicare billing of $85,474. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Birmingham, AL
- Active Since 07/13/2006
- Last Updated 06/01/2023
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1023033917
Products in Payments
- Prolia (Biological) $51,184
- KRYSTEXXA (Biological) $28,591
- Kineret (Drug) $14,037
- KINERET (Drug) $8,890
- Tymlos (Biological) $8,283
- KEVZARA (Drug) $8,200
- EVENITY (Biological) $7,814
- KRYSTEXXA (Drug) $7,369
- KEVZARA (Biological) $6,101
- CD cobas Reagents (Device) $5,844
- Rituxan (Biological) $5,466
- ZURAMPIC (Drug) $5,368
- Actemra (Biological) $4,180
- Privigen (Biological) $4,000
- Adempas (Drug) $3,080
- FORTEO (Drug) $2,700
- Tymlos (Drug) $2,502
- Uloric (Drug) $1,064
- Humira (Biological) $110.14
- NO_PRODUCT (Drug) $21.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Birmingham
Jeffrey Curtis, Md, MD
Rheumatology — Payments: $976,985
Rheumatology $976,985
Dr. David Mclain, M.d, M.D
Rheumatology — Payments: $376,451
Rheumatology $376,451
Maria Danila
Rheumatology — Payments: $55,220
Rheumatology $55,220
Dr. Greg Eudy, Md Pc, MD PC
Rheumatology — Payments: $36,953
Rheumatology $36,953
Angelo Gaffo-Llontop
Rheumatology — Payments: $17,265
Rheumatology $17,265
John Morgan, Md, MD
Rheumatology — Payments: $13,153
Rheumatology $13,153